SCHEMBL367981

SCHEMBL367981

CNCc1csc(NC(=O)O)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
KMT2A Q03164 2/20 0.51
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
GAA P10253 1/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.44
TP53 P04637 1/20 0.44
PDE5A O76074 2/20 0.44
CDK5 Q00535 2/20 0.43
CDK5R1 Q15078 2/20 0.43
KDM4E B2RXH2 1/20 0.43
AOC3 Q16853 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4299959 0.87 SMN1; SMN2 (0.69) SMN1; SMN2KMT2ANPC1RAB9ALMNA
SCHEMBL2664522 0.82 KDM4E (0.66) SMN1; SMN2NPC1RAB9APDE5ACDK5
SCHEMBL465934 0.81 SMN1; SMN2 (0.51) SMN1; SMN2KMT2ANPC1RAB9AGAA
SCHEMBL17674539 0.79 SMN1; SMN2 (0.50) SMN1; SMN2KMT2ANPC1RAB9AGAA
SCHEMBL353851 0.79 SMN1; SMN2 (0.73) SMN1; SMN2KMT2ANPC1RAB9AGAA
SCHEMBL12468610 0.79 SMN1; SMN2 (0.50) SMN1; SMN2KMT2ANPC1RAB9AGAA
SCHEMBL3511778 0.79 SMN1; SMN2 (0.50) SMN1; SMN2KMT2ANPC1RAB9AGAA
SCHEMBL353953 0.79 SIRT1 (0.48) SMN1; SMN2KMT2ANPC1RAB9AGAA
SCHEMBL3653731 0.79 ROCK2 (0.61)
SCHEMBL1742457 0.79 SMN1; SMN2 (0.55) SMN1; SMN2KMT2ANPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA SMN1; SMN2 2356/4885KMT2A 1210/4885NPC1 3444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.